Status:
UNKNOWN
Prospective Evaluation of Gastrointestinal and Genitourinary Side Effects of Pelvic Radiotherapy
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Radiotherapy Side Effects
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Most patients who have pelvic radiotherapy (RT) as a treatment for cancer experience some degree of acute gastrointestinal (GI) and genitourinary (GU) toxicities. If physicians can anticipate, identif...
Detailed Description
BACKGROUND: The classic endpoints in cancer clinical trials typically include tumour control rate, overall survival, or disease-free survival; however, it is becoming essential to consider the impact ...
Eligibility Criteria
Inclusion
- All patients 18 years or older
- Patients receiving standard or hypo-fractionated RT for curative intent to a pelvic malignancy
- Patients' ECOG performance status must be 0-2
- Patients should be able to give informed consent, read and understand English or French
- Patients should have access to the internet
Exclusion
- Patients who have received prior pelvic radiation
- Patients who are at the end-of-life (expected survival less than six months)
- patients with significant cognitive dysfunction are excluded.
- patients included in other QoL studies, which may increase the patient burden and bias the answering of questionnaires
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT05407116
Start Date
June 1 2022
End Date
June 1 2023
Last Update
June 7 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.